Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7380541 | 0.85 | LMNA (0.56) | MAPTALDH1A1POLBHIF1AMEN1 | |
| SCHEMBL29702837 | 0.82 | TSHR (0.50) | TDP1ATMMAPTALDH1A1POLB | |
| SCHEMBL28165237 | 0.82 | TSHR (0.50) | TDP1ATMMAPTALDH1A1POLB | |
| SCHEMBL2561000 | 0.81 | ATM (0.58) | TDP1ATMMAPTALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL28375819 | 0.81 | TSHR (0.48) | TDP1ATMMAPTALDH1A1POLB | |
| SCHEMBL10437967 | 0.80 | ATM (0.56) | TDP1ATMMAPTALDH1A1POLB | |
| SCHEMBL12287011 | 0.79 | TDP1 (0.60) | TDP1MAPTALDH1A1POLBMEN1 | |
| SCHEMBL9297681 | 0.78 | GPR35 (0.56) | TDP1MAPTALDH1A1POLBHIF1A | |
| SCHEMBL1830783 | 0.78 | TSHR (0.58) | TDP1MAPTALDH1A1POLBMEN1 | |
| SCHEMBL1828950 | 0.78 | ALDH1A1 (0.58) | ATMMAPTALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023151359-A1 | TETRAHYDROCARBAZOLE DERIVATIVE AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳湾实验室 | 2023-08-17 | — | — | WO | disclosed |
| CN-114560804-A | Tetrahydrocarbazole derivative and preparation method and application thereof | 深圳湾实验室 | 2022-05-31 | — | — | CN | disclosed |
| EP-1523475-B1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-12-23 | — | — | EP | disclosed |
| CN-1304371-C | Heterocyclically substituted benzoylureas, medicaments thereof and use for producing medicaments | AVENTIS PHARMA GMBH (DE) | 2007-03-14 | — | — | CN | disclosed |
| US-20070021474-A1 | Heterocyclically Substituted Benzoylureas, Process For Their Preparation and Their Use as Pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| US-7138414-B2 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-21 | — | — | US | disclosed |
| CN-1261419-C | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase | AVENTIS PHARMA DENTSCHLAND GMD (DE) | 2006-06-28 | — | — | CN | disclosed |
| CN-1668593-A | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA GMBH (DE) | 2005-09-14 | — | — | CN | disclosed |
| EP-1523475-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2005-04-20 | — | — | EP | disclosed |
| EP-1482929-A1 | USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE | Aventis Pharma Deutschland GmbH (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-20040152743-A1 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-05 | — | — | US | disclosed |
| EP-1263745-B1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONE AND USE THEREOF FOR INHIBITING HORMONE-SENSITIVE LIPASE | AVENTIS PHARMA GMBH (DE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2004007455-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-25 | — | — | US | disclosed |
| WO-2003072098-A1 | USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-04 | — | — | WO | disclosed |
| CN-1416424-A | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase | AVENTIS PHARMA DENTSCHLAND GMD (DE) | 2003-05-07 | — | — | CN | disclosed |
| EP-1263745-A1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONE AND USE THEREOF FOR INHIBITING HORMONE-SENSITIVE LIPASE | Aventis Pharma Deutschland GmbH (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-6369088-B2 | ANTIDIABETIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| US-20010031772-A1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2001-10-18 | — | — | US | disclosed |
| WO-2001066531-A1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONE AND USE THEREOF FOR INHIBITING HORMONE-SENSITIVE LIPASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021474-A1 | Heterocyclically Substituted Benzoylureas, Process For Their Preparation and Their Use as Pharmaceuticals | SLC5A2, CYP1A2, HBB | TDP1 3078/4885ATM 3758/4885MAPT 4315/4885 |
| US-20010031772-A1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals | CNR1, PTGER1, CNR2 | TDP1 3897/4885ATM 4879/4885MAPT 4852/4885 |
| US-20040152743-A1 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | SLC5A2, CYP1B1, CYP2C19 | TDP1 2188/4885ATM 3758/4885MAPT 4316/4885 |
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | PNLIP, CEL, LIPE | TDP1 596/4885ATM 4360/4885MAPT 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.